This video, part of the "Demonic in Internal Medicine" series, provides a comprehensive overview of gout, a form of arthritis caused by uric acid crystal deposition. It details the pathophysiology, including factors leading to decreased urate excretion (using the "CANT LEAP" mnemonic for drugs) and increased urate production. Clinical manifestations such as mono/oligoarthritis (particularly podagra), tophi, and kidney involvement (urolithiasis, nephropathy) are discussed. The lecture outlines diagnostic investigations, emphasizing synovial fluid analysis for needle-shaped, negatively birefringent monosodium urate crystals, contrasting them with pseudogout crystals. Finally, it covers acute management with NSAIDs, corticosteroids, and colchicine, and long-term strategies focusing on diet, xanthine oxidase inhibitors (allopurinol, febuxostat), uricosuric agents (probenecid), and prophylaxis, while also touching on other crystal arthropathies.
Summarizing Gout: Causes, Diagnosis, and Management
1:51 Pathophysiology of Gout: Gout results from an imbalance of decreased uric acid excretion or increased production, leading to uric acid crystal deposition in joints, skin (tophi), and kidneys, causing arthritis and potential renal failure. Estrogen generally protects premenopausal women by increasing urate excretion.
2:00 Common Precipitants: Acute gout attacks can be triggered by factors such as surgery, dehydration, fasting, binge eating or drinking, intense exercise, and trauma.
2:31 Causes of Decreased Urate Excretion: Medications commonly causing decreased urate excretion include Cyclosporine, Alcohol, Nicotinic acid, Thiazide diuretics, Loop diuretics, Ethambutol, Pyrazinamide, and low-dose Aspirin (mnemonic: CANT LEAP).
3:02 Causes of Increased Urate Production: Factors leading to increased uric acid production include metabolic syndrome (obesity, hyperlipidemia, hypertension), increased metabolism (alcohol, hemolytic anemia, psoriasis, Lesch-Nyhan syndrome), and neoplastic conditions (myeloproliferative/lymphoproliferative diseases, chemotherapy).
3:25 Clinical Manifestations: Gout primarily presents as asymmetric mono- or oligoarthritis, often affecting the first metatarsophalangeal (MTP) joint (podagra) in 75% of cases. Other manifestations include tophi (yellowish-white uric crystal collections in subcutaneous tissues) and kidney involvement (radiolucent urolithiasis, acute/chronic nephropathy).
5:04 Key Diagnostic Finding - Crystals: Synovial fluid analysis is definitive, showing predominantly neutrophilic infiltrate and needle-shaped monosodium urate crystals with strong negative birefringence (yellow when parallel to polarized light). This differentiates gout from pseudogout (calcium pyrophosphate deposition disease), which features rhomboid-shaped crystals with positive birefringence (blue when parallel).
6:02 Acute Gout Management: Treatment for acute attacks includes NSAIDs (first-line, avoid in renal/hepatic failure), systemic or intra-articular corticosteroids, and Colchicine (0.6mg twice daily; avoid older hourly dosing regimens due to side effects).
7:34 Long-term Gout Management: Long-term strategies involve dietary changes (reducing red meats/seafood, avoiding beer/sugary drinks), urate-lowering therapies like Allopurinol (first-line xanthine oxidase inhibitor, requires renal dose adjustment, not started during acute attacks) or Febuxostat (newer option for allopurinol intolerance/renal failure), and uricosuric agents like Probenecid.
8:40 Prophylaxis and Treatment Targets: Colchicine (0.6mg BD for six months) is used for prophylaxis against recurrent attacks. Long-term therapy is considered for frequent attacks (>3/year), tophi, or uric acid overproduction. The target serum uric acid level is generally below 362 micromol/L (0.35 mmol/L) or even lower (<0.3 mmol/L) if tophi are present.
9:41 Distinguishing Other Crystal Arthropathies: The video briefly differentiates gout from Calcium Pyrophosphate Deposition Disease (Pseudogout) based on crystal morphology and birefringence, and mentions Basic Calcium Phosphate crystals and issues in dialysis patients (calcium oxalate, amyloidosis).